Cannabinoid receptors connected to cell viability are expressed by glial cells (Stella, 2010).
Cancer cells overexpress cannabinoid receptors such as CB2 and GPR55 compared to non-cancer glial cells.
There is a correlation between this overexpression and disease prognosis where higher overexpression of CB2 being observed in most aggressive tumors (Calatozzolo et al., 2007; Ellert-Miklaszewska et al., 2007; Sánchez et al., 2001).
Several glioblastoma studies reported that CBD also exhibited anti-cancer activities.
CBD was shown to exhibit antiproliferative and anti-invasive activities on glioblastoma cells and stimulate differentiation of glioblastoma stem cells (GSCs) and apoptosis process (Hernán Pérez de la Ossa et al., 2013; Nabissi et al., 2015).
In glioma xenografts, tumor growth was reduced by about 20% upon CBD (7.5 mg/kg/day). 7.5 mg/kg/day of THC showed similar effects and combined administration of THC and CBD decreased tumor growth to a higher extent (Torres et al., 2011).
In human glioblastoma cell lines, cancer cell viability and proliferation were reduced by CBD (Deng et al., 2016).
CBD was also found to be involved in ameliorating the effectiveness of other anti-cancer drugs like temozolomide, carmustine, or doxorubicin via TRPV-2 (Nabissi et al., 2013).